Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Taisho to develop and commercialize Ablynx's rheumatoid arthritis drug ozoralizumab in Japan Belgian biopharmaceutical firm Ablynx has entered a licence agreement with Japan-based Taisho Pharmaceutical to develop and commercialize its anti- TNFα nanobody, ozoralizumab, for the treatment of patients with rheumatoid arthritis (RA) in Japan. Contract Research & Services > Contract Services > News
Nutra Pharma selects Pickwick Capital Partners for strategic advisory services Nutra Pharma, a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services.
Production & Manufacturing > OTC > News Medical Marijuana holds investment in AXIM Biotechnologies Medical Marijuana would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies (AXIM), a cutting-edge biotechnology innovator.
Production & Manufacturing > OTC > News Cellular Biomedicine completes acquisition of CD40LGVAX vaccine Cellular Biomedicine Group (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced it has completed the previously announced acquisition of Blackbird Bio Finance and University of South Florida's (Licensor) next generation GVAX vaccine's (CD40LGVAX) related technologies and technical knowledge.
Drug Research > Drug Delivery > News
Immunovaccine begins Phase I trial with DPX-RSV vaccine Immunovaccine, a clinical stage vaccine and immunotherapy company, announced that it has enrolled the first healthy adult volunteer in a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine.
Drug Research > Drug Delivery > News AMAG Pharma agrees to acquire Cord Blood Registry for $700m By PBR Staff Writer
US-based AMAG Pharmaceuticals has agreed to acquire the world's largest newborn stem cell collection and storage firm, Cord Blood Registry (CBR) for $700m.
Production & Manufacturing > Manufacturing > News Immune Pharma inks license and research deal with Yissum for AmiKet Nano Immune Pharmaceuticals (IMNP) has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet, pursuant to the parties' existing binding memorandum of understanding from March 2015.
Contract Research & Services > Contract Services > News

Latest News and Insight by Sector

Production & Manufacturing

Nutra Pharma selects Pickwick Capital Partners for strategic advisory services
Nutra Pharma, a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services.
Production & Manufacturing > OTC > News
Medical Marijuana holds investment in AXIM Biotechnologies
Medical Marijuana would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies (AXIM), a cutting-edge biotechnology innovator.
Production & Manufacturing > OTC > News

Drug Research

Cellular Biomedicine completes acquisition of CD40LGVAX vaccine
Cellular Biomedicine Group (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced it has completed the previously announced acquisition of Blackbird Bio Finance and University of South Florida's (Licensor) next generation GVAX vaccine's (CD40LGVAX) related technologies and technical knowledge.
Drug Research > Drug Delivery > News
Immunovaccine begins Phase I trial with DPX-RSV vaccine
Immunovaccine, a clinical stage vaccine and immunotherapy company, announced that it has enrolled the first healthy adult volunteer in a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine.
Drug Research > Drug Delivery > News

Inward Investment

PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News
Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Immune Pharma inks license and research deal with Yissum for AmiKet Nano
Immune Pharmaceuticals (IMNP) has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet, pursuant to the parties' existing binding memorandum of understanding from March 2015.
Contract Research & Services > Contract Services > News
Eolas, AstraZeneca to develop orexin-1 receptor antagonist to treat multiple indications
By PBR Staff Writer
US-based Eolas Therapeutics and AstraZeneca have entered into a worldwide license and partnership agreement on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications.
Contract Research & Services > Contract Services > News

Automation

BSN medical expand lymphoedema therapy solutions with FarrowMed acquisition
BSN medical continues to strengthen its position as a market leading provider of lymphoedema therapy solutions by acquiring FarrowMed and its range of patented FarrowWrap and related compression garment technologies, which focus on the management of lymphoedema and venous disease.
Automation > IT & Software > News
SteadyMed, Cardiome partner to commercialize PAH drug Trevyent outside US
By PBR Staff Writer
US pharmaceutical firm SteadyMed has entered into an exclusive license and supply agreement with Canada-based Cardiome to commercialize Trevyent in certain regions outside the US if the drug is approved to treat pulmonary arterial hypertension (PAH), in such regions.
Automation > IT & Software > News

Regulatory Affairs

Theravance gets marketing authorization for Vibativ in Russia to treat gram-positive bacterial infections
By PBR Staff Writer
Theravance Biopharma has received marketing authorization from the Ministry of Health of the Russian Federation for Vibativ (telavancin) to treat complicated skin and soft tissue infections, as well as nosocomial pneumonia, caused by Gram-positive bacteria, including methicillin-resistance Staphylococcus aureus (MRSA).
Regulatory Affairs > News
Aridis gets FDA fast track status for pneumonia drug Aerucin
By PBR Staff Writer
US-based Aridis Pharmaceuticals has received fast track designation from the US Food and Drug Administration (FDA) for its fully human monoclonal antibody Aerucin to treat hospital-acquired and ventilator-associated pneumonia caused by pseudomonas aeruginosa.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery